BRPI0920513A2 - derivados de pirina ou pirazina para tratar hcv - Google Patents
derivados de pirina ou pirazina para tratar hcvInfo
- Publication number
- BRPI0920513A2 BRPI0920513A2 BRPI0920513A BRPI0920513A BRPI0920513A2 BR PI0920513 A2 BRPI0920513 A2 BR PI0920513A2 BR PI0920513 A BRPI0920513 A BR PI0920513A BR PI0920513 A BRPI0920513 A BR PI0920513A BR PI0920513 A2 BRPI0920513 A2 BR PI0920513A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrine
- pyrazine derivatives
- treat hcv
- hcv
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19446908P | 2008-09-26 | 2008-09-26 | |
| PCT/EP2009/062103 WO2010034671A1 (en) | 2008-09-26 | 2009-09-18 | Pyrine or pyrazine derivatives for treating hcv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0920513A2 true BRPI0920513A2 (pt) | 2019-09-24 |
Family
ID=41334364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920513A BRPI0920513A2 (pt) | 2008-09-26 | 2009-09-18 | derivados de pirina ou pirazina para tratar hcv |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8067442B2 (pt) |
| EP (1) | EP2334662A1 (pt) |
| JP (1) | JP2012503620A (pt) |
| KR (1) | KR20110061640A (pt) |
| CN (1) | CN102164909A (pt) |
| AR (1) | AR073315A1 (pt) |
| AU (1) | AU2009295981A1 (pt) |
| BR (1) | BRPI0920513A2 (pt) |
| CA (1) | CA2736472A1 (pt) |
| MX (1) | MX2011002846A (pt) |
| TW (1) | TW201020250A (pt) |
| WO (1) | WO2010034671A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752611B2 (en) | 2009-02-27 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| EP2421831A1 (en) * | 2009-04-25 | 2012-02-29 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| EP2480533A1 (en) * | 2009-09-21 | 2012-08-01 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| EP2590960B1 (en) * | 2010-07-07 | 2014-06-11 | F.Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| TW201536789A (zh) | 2013-07-29 | 2015-10-01 | Enanta Pharm Inc | Ｃ型肝炎病毒抑制劑 |
| EP3478680B1 (en) * | 2016-06-29 | 2020-04-22 | H. Hoffnabb-La Roche Ag | Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| EP3638664A1 (en) * | 2017-06-14 | 2020-04-22 | European Molecular Biology Laboratory | Benzofuran amides and heteroaromatic analogues thereof for use in therapy |
| CN116239562A (zh) * | 2021-12-07 | 2023-06-09 | 江苏师范大学 | 一种以苯并呋喃酮为原料合成盐酸多塞平的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9226537D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| EP1292310A1 (en) * | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Novel anti-infectives |
| BRPI0514591A (pt) * | 2004-08-23 | 2008-06-17 | Hoffmann La Roche | compostos antivirais heterocìclicos |
| KR20090094154A (ko) * | 2006-12-22 | 2009-09-03 | 쉐링 코포레이션 | Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체 |
| MX2010002318A (es) | 2007-08-29 | 2010-03-22 | Schering Corp | Derivados azaindol 2,3-sustituidos para tratar infecciones virales. |
| CN101842376A (zh) | 2007-08-29 | 2010-09-22 | 先灵公司 | 四环吲哚衍生物及其用于治疗或预防病毒感染 |
| EP2197842B1 (en) | 2007-08-29 | 2012-05-23 | Schering Corporation | 2, 3-substituted indole derivatives for treating viral infections |
| KR101552474B1 (ko) | 2007-09-17 | 2015-09-11 | 애브비 바하마스 리미티드 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
| EP2377854A1 (en) | 2007-09-17 | 2011-10-19 | Abbott Laboratories | N-phenyl-dioxo-hydropyrimidines useful as hepatitis C virus (HCV) inhibitors |
| CN101842360B (zh) | 2007-09-17 | 2014-12-17 | 艾伯维巴哈马有限公司 | 抗感染嘧啶及其用途 |
| EP2222672B1 (en) | 2007-11-16 | 2013-12-18 | Merck Sharp & Dohme Corp. | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
| JP5249344B2 (ja) | 2007-11-16 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | ヘテロ環の３位が置換されたインドール誘導体およびその使用 |
| CN102015661B (zh) * | 2008-04-29 | 2014-05-14 | 默克专利有限公司 | 芳基吡嗪酮衍生物胰岛素分泌刺激剂、获得它们的方法及其用于治疗糖尿病的用途 |
| KR20110033291A (ko) * | 2008-07-23 | 2011-03-30 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
| CA2755023C (en) | 2009-03-25 | 2016-12-13 | Abbott Laboratories | Antiviral compounds and uses thereof |
| WO2010111436A2 (en) | 2009-03-25 | 2010-09-30 | Abbott Laboratories | Antiviral compounds and uses thereof |
-
2009
- 2009-09-18 KR KR1020117009482A patent/KR20110061640A/ko not_active Application Discontinuation
- 2009-09-18 WO PCT/EP2009/062103 patent/WO2010034671A1/en active Application Filing
- 2009-09-18 BR BRPI0920513A patent/BRPI0920513A2/pt not_active IP Right Cessation
- 2009-09-18 CN CN2009801380378A patent/CN102164909A/zh active Pending
- 2009-09-18 JP JP2011528296A patent/JP2012503620A/ja active Pending
- 2009-09-18 CA CA2736472A patent/CA2736472A1/en not_active Abandoned
- 2009-09-18 MX MX2011002846A patent/MX2011002846A/es not_active Application Discontinuation
- 2009-09-18 AU AU2009295981A patent/AU2009295981A1/en not_active Abandoned
- 2009-09-18 EP EP09783162A patent/EP2334662A1/en not_active Withdrawn
- 2009-09-23 TW TW098132107A patent/TW201020250A/zh unknown
- 2009-09-24 AR ARP090103673A patent/AR073315A1/es not_active Application Discontinuation
- 2009-09-25 US US12/566,896 patent/US8067442B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011002846A (es) | 2011-04-07 |
| CA2736472A1 (en) | 2010-04-01 |
| AU2009295981A1 (en) | 2010-04-01 |
| TW201020250A (en) | 2010-06-01 |
| JP2012503620A (ja) | 2012-02-09 |
| WO2010034671A1 (en) | 2010-04-01 |
| CN102164909A (zh) | 2011-08-24 |
| EP2334662A1 (en) | 2011-06-22 |
| US8067442B2 (en) | 2011-11-29 |
| KR20110061640A (ko) | 2011-06-09 |
| AR073315A1 (es) | 2010-10-28 |
| US20100081658A1 (en) | 2010-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0920513A2 (pt) | derivados de pirina ou pirazina para tratar hcv | |
| BRPI0816994A2 (pt) | Derivado uracila ou timina para tratar hepatite c | |
| DE112009004699A5 (de) | Elektrochirurgisches System | |
| BRPI0923497A2 (pt) | derivados de piridazinona | |
| BRPI0914789A2 (pt) | efeitos sinérgicos | |
| DK2252380T3 (da) | Skateboard | |
| DK2285786T3 (da) | Quinoxalindion-derivater | |
| BRPI0911161A2 (pt) | derivado de piridazinona | |
| BRPI0908346A2 (pt) | beteria | |
| BRPI0914305A2 (pt) | Compostos de piridazina carboxamida substituída como compostos inibidores da quinase | |
| BRPI0914676A2 (pt) | derivados de n-óxido de pirazina substituídos | |
| BRPI0922347A2 (pt) | métodos para prevenir ou reduzir carcinogênese de colón | |
| BRPI0911199A2 (pt) | microbiocidas | |
| BRPI0921679A2 (pt) | composto útil para tratar celulite | |
| BRPI0913935A2 (pt) | misturas antimicrobianas sinérgicas | |
| BRPI0822264A2 (pt) | Dapsona para tratar rosácea | |
| BRPI0909425A2 (pt) | derivado de hidroxiquinoxalinacarboxamida | |
| FR2930124B1 (fr) | Meuble demontable | |
| BRPI0909764A2 (pt) | compostos terapêuticos | |
| BRPI0906879A2 (pt) | Compostos terapêuticos | |
| FR2928612B1 (fr) | Tracteur | |
| TH117354B (th) | อนุพันธ์ของพิริดาซิโนน | |
| FI20085700A0 (fi) | Parannettu hierontalaite | |
| ES1069199Y (es) | Accesorio de viaje para dormir sentado | |
| TH117340B (th) | อนุพันธ์ไพริดาซิโนน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |